- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.11. | SenzaGen AB: SenzaGen completes the acquisition of Alcyomics | 107 | GlobeNewswire (Europe) | SenzaGen AB (publ) has today completed the acquisition of all shares in Alcyomics Ltd, a leading UK-based provider of non-animal immunotoxicology solutions for drug development, including biological... ► Artikel lesen | |
| 05.11. | SenzaGen AB: SenzaGen's interim report January-September 2026 | Increased revenue and efficiency deliver a profitable quarter; acquisition expands future commercial opportunities | 103 | GlobeNewswire (Europe) | Message from the CEO"SenzaGen continued to grow and reported its first positive quarterly operating profit (EBIT) of SEK 1.1 million in the third quarter. EBITDA was positive both for the quarter and... ► Artikel lesen | |
| 02.11. | SenzaGen AB: SenzaGen subsidiary secures SEK 2.8 million order from existing customer | 131 | GlobeNewswire (Europe) | SenzaGen's subsidiary VitroScreen has secured an order worth SEK 2.8 million from an existing customer for non-animal efficacy testing. The order follows successful assignments during 2026 and reflects... ► Artikel lesen | |
| SENZAGEN Aktie jetzt für 0€ handeln | |||||
| 28.10. | SenzaGen AB: SenzaGen acquires Alcyomics, a leading UK-based provider of non-animal immunotoxicology solutions for drug development | 198 | GlobeNewswire (Europe) | SenzaGen AB (publ) ("SenzaGen" or the "Group") has today entered into an agreement to acquire Alcyomics Ltd ("Alcyomics"). Alcyomics specializes in non-animal safety testing of pharmaceuticals in the... ► Artikel lesen | |
| 20.08. | SenzaGen AB Q2 Sales Increase | 1 | RTTNews | ||
| 20.08. | SenzaGen: Umsatz im zweiten Quartal steigt um 13 % dank Erholung bei VitroScreen | 1 | Investing.com Deutsch | ||
| 20.08. | SenzaGen AB: SenzaGen's interim report January-June 2026 | Continued strong development in Q2 2026 - 13% growth with positive cash flow | 212 | GlobeNewswire (Europe) | Message from the CEO "Revenue for the second quarter increased to SEK 15.3 million, corresponding to 13 % growth (18% at constant exchange rates). At the same time, we maintained an effective cost... ► Artikel lesen | |
| 09.06. | SenzaGen AB: SenzaGen's subsidiary receives two orders within non-animal testing with a total value of SEK 2.4 million | 264 | GlobeNewswire (Europe) | SenzaGen's subsidiary VitroScreen has received two orders from existing customers for non-animal testing. The total order value amounts to SEK 2.4 million, with the majority of revenues expected to... ► Artikel lesen | |
| 12.05. | SenzaGen AB: Report from AGM of SenzaGen AB on 12 May 2026 | 330 | GlobeNewswire (Europe) | The Annual General Meeting (AGM) of SenzaGen held on today's date, 12 May 2026 in Lund, resolved to pass all proposals presented by the board and shareholders.
Adoption of income statement and balance... ► Artikel lesen | |
| 12.05. | SenzaGen AB: SenzaGen's interim report January-March 2026 | 10% sales growth alongside increased attention to non-animal methods | 339 | GlobeNewswire (Europe) | Message from the CEO"We started the year with 10 percent growth despite negative foreign exchange effects and the impact of a subsidiary undergoing a transition. At the same time, we maintained our... ► Artikel lesen | |
| 15.04. | SenzaGen AB: SenzaGen's subsidiary receives strategically important order | 347 | GlobeNewswire (Europe) | SenzaGens's subsidiary VitroScreen has received an order from an existing customer for non-animal efficacy testing. The order includes studies using the proprietary platform VitroScreenORA® and is carried... ► Artikel lesen | |
| 31.03. | XFRA NEW INSTRUMENTS AVAILABLE ON 31.03.2026 | 816 | Xetra Newsboard | The following instruments on XETRA do have their first trading 31.03.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 31.03.2026
Aktien
1 SE0009697204 Boho Group AB
2 SE0008321608... ► Artikel lesen | |
| 30.03. | SenzaGen AB: SenzaGen wins new global cosmetics group as customer | 325 | GlobeNewswire (Europe) | SenzaGen has received a first order from a leading global group in the cosmetics sector, one of the company's prioritized industry segments. The customer will begin by testing with GARD®skin Dose-Response... ► Artikel lesen | |
| 13.02. | SenzaGen AB: SenzaGen carries out a directed issue of approximately SEK 17.5 million to the institutional investor Eiffel Investment Group | 311 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE ANNOUNCED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND... ► Artikel lesen | |
| 13.02. | SenzaGen AB: SenzaGen's Year-End Report 2025 | SenzaGen closes the year with continued strong GARD sales | 350 | GlobeNewswire (Europe) | Message from the CEO
"As previously stated in the half-year report, 2025 performance was stronger in the second half of the year. GARD® continued to strengthen its market position with positive sales... ► Artikel lesen | |
| 16.12.25 | SenzaGen AB: SenzaGen further strengthens US market position with 1.5 MSEK order from global chemical industry leader | 265 | GlobeNewswire (Europe) | SenzaGen continues to solidify its role as an important partner for customers with high safety testing requirements, securing an assignment worth approximately 1.5 MSEK from a leading American chemical... ► Artikel lesen | |
| 20.11.25 | SenzaGen AB: SenzaGen opens expanded laboratory facilities to strengthen capacity in line with 2030 growth plan | 293 | GlobeNewswire (Europe) | To support its recently announced growth strategy through 2030, SenzaGen has opened expanded office and laboratory facilities in Lund. This investment strengthens the company's ability to meet the growing... ► Artikel lesen | |
| 18.11.25 | SenzaGen AB: UK signals shift to non-animal testing - new opportunities for SenzaGen | 292 | GlobeNewswire (Europe) | The UK government has recently unveiled a national strategy to accelerate the phase-out of animal testing in research and product development. The plan includes clear timelines and governance to ensure... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,395 | +0,35 % | Ihre wichtigsten Termine: Spannende Updates von: Moderna, Krones, Daimler Truck, Under Armour & Brookfield | © Foto: Bodo Schackow/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag Enthaltene Werte: CA29250N1050... ► Artikel lesen | |
| MODERNA | 224,20 | -0,27 % | Moderna zwischen Durchbruch und Milliardenrisiko | Moderna erlebt einen bemerkenswerten Wandel an der Börse. Noch vor wenigen Monaten dominierte die Sorge um schrumpfende Corona-Umsätze und hohe Forschungskosten. Inzwischen rückt eine ganz andere Perspektive... ► Artikel lesen | |
| ERASCA | 16,170 | +4,46 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| PRIME MEDICINE | 3,850 | -1,28 % | Cathie Wood's ARK sells Absci stock, buys Prime Medicine | ||
| EVOTEC | 3,116 | -0,06 % | Kurs-Drama bei Palantir! Evotec mit Aufwärtsdrang! Kaufgelegenheit bei Lahontan Gold nach der Konsolidierung! | Die Märkte drehen derzeit teilweise komplett durch. Chipaktien korrigieren prozentual zweistellig. Investoren befürchten, dass die KI-Blase platzt oder das Wachstum nicht mehr in dem Maße weitergeht... ► Artikel lesen | |
| BIONTECH | 78,70 | +0,77 % | 16,6 Milliarden Euro bei BioNTech, 15 neue Therapeuten bei Emyria - woran die Psychedelika-Medizin wirklich hängt | ||
| VERADERMICS | 148,00 | -0,52 % | Teure Lektionen: 54 % SpaceX-Crash: Droht Anthropic-Anlegern jetzt die nächste IPO-Falle? | © Foto: Jonathan Raa - NurPhotoErst der Mega-Hype, dann der Absturz: SpaceX verlor mehr als die Hälfte seines Börsenwerts vom Hoch. Jetzt steht Anthropic vor dem nächsten Billionen-IPO. Was Anleger... ► Artikel lesen | |
| PEPGEN | 5,645 | +22,45 % | PepGen prices $125M public offering at $5 per share | ||
| COGENT BIOSCIENCES | 31,130 | -1,49 % | Cogent Biosciences auf Guggenheim-Konferenz: Marktstart rückt näher | ||
| KYMERA THERAPEUTICS | 136,49 | -0,11 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| ALAMAR BIOSCIENCES | 32,040 | +1,71 % | Alamar Biosciences, Inc.: Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine | Alamar's NULISAseq Immune 340 and NULISAseq Neuro 220 panels will be used to investigate disease progression, biological subtypes and treatment responseFREMONT, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,440 | -2,19 % | Stifel cuts Summit Therapeutics stock price target on valuation | ||
| TANGO THERAPEUTICS | 24,510 | +0,86 % | Jefferies raises Tango Therapeutics stock price target on trial data | ||
| BEAM THERAPEUTICS | 25,170 | +0,08 % | Jones Trading initiates Beam Therapeutics stock coverage with buy rating | ||
| TEMPUS AI | 73,02 | +1,23 % | Ihre wichtigsten Termine: Frische Q-Zahlen von Apple, Palantir, BioMarin, Marriott International, Fox Corp | © Foto: Andrej Sokolow - dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag Enthaltene Werte: US0378331005... ► Artikel lesen |
Das Unternehmen SENZAGEN AB kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,011 (-2,53 %) liegt der Kurs bei 0,424 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SENZAGEN AB finden Sie auf Wallstreet Online.